Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP (CIGMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01420744|
Recruitment Status : Completed
First Posted : August 22, 2011
Last Update Posted : July 29, 2015
|Condition or disease||Intervention/treatment||Phase|
|Community Acquired Pneumonia||Drug: BT086 Drug: 1% Human Albumin infusion||Phase 2|
Severe Community-Acquired Pneumonia (sCAP) is usually defined clinically as pneumonia acquired from outside the hospital (CAP) that requires intensive medical care. Mortality of (s)CAP patients admitted to ICU range from 35-58% depending on time and admission of the patient and has not much improved in the last years.
BT086 contains a sufficient number of antibodies against the most frequent pathogens as well as antibodies against lipopolysaccharides and lipid A. Therefore, it can be assumed that administration of BT086 early in the clinical course of a severe infection such as sCAP may provide an effective adjunctive treatment to standard antibiotic therapy for sCAP patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||February 2015|
|Actual Study Completion Date :||April 2015|
|Experimental: BT086 infusion||
BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.
Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period.
|Placebo Comparator: 1% Human Albumin infusion||
Drug: 1% Human Albumin infusion
1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.
Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.
Treatment will be administered over a 5-day period.
Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)
- Ventilator Free Days (VFDs) [ Time Frame: 28 days ]VFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.
- 28-day all cause mortality [ Time Frame: 28 days (672 hours from randomization) ]All patients will be classified as either "alive at Study Day 28" or, if dead, "dead at Study Day 28", regardless of cause of death.
- 28-day pneumonia-cause mortality [ Time Frame: 28 days (672 hours from randomization) ]All patients will be classified as either "alive at Study Day 28" or, if dead, "dead at Study Day 28, with pneumonia as cause of death".
- Time (days) to discharge from ICU [ Time Frame: 28 days ]The date and time of admission to and discharge from the ICU will be recorded in the Case Report Form (CRF). The time to discharge from the ICU will be calculated as the number of days spent in the ICU.
- Time (days) to discharge from hospital [ Time Frame: 28 days ]The date and time of admission to and discharge from the hospital will be recorded in the CRF. The time to discharge from the hospital will be calculated as the number of days spent in the hospital.
- SOFA: Score Sequential Organ Failure Assessment [ Time Frame: 28 days ]Each organ system (cardiovascular, haematology, hepatic, renal, respiratory) will be scored using the SOFA methodology.For analysis, a patient will receive a score on each day (Study Days 1-7, Day 14, Day 21, and Day 28). Mean changes in organ function scores over time and percentages of patients whose organ function has resolved will be compared between treatment groups.
- Vasopressor-free days [ Time Frame: 28 days ]
Vasopressor-free days will be calculated in a similar manner to VFDs, as described above. Vasopressors include dobutamine, epinephrine, dopamine, and norepinephrine.
A day is considered as a vasopressor-free day if a patient does not receive
- Dobutamine >2.5 µg/kg/min or/and
- Epinephrine (adrenalin) >=2.5 µg/min or/and
- Dopamine >=2.5 µg/kg/min or/and
- Norepinephrine >=0.014 µg/kg/min for 4 hours per day.
- Glasgow Coma Score [ Time Frame: 28 days ]The Glasgow Coma Scale will be scored using the Glasgow Coma Score methodology. The patient will be assessed by calculating the score on each study day (Day -1 through to Day 28).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01420744
|Palma de Mallorca, Spain|
|Santiago de Compostela, Spain|
|Cardiff, United Kingdom|
|Kings Lynn, Norfolk, United Kingdom|
|London, United Kingdom|
|London, United Kingdom|
|Poole, Dorset, United Kingdom|
|Reading, Berkshire, United Kingdom|
|Principal Investigator:||Tobias Welte, MD||Hannover Medical School|